Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
Bart Hoogveldt1, Benoît Rive2, Johan Severens3, Khaled Maman4, Chantal Guilhaume51Field Product Management, Lundbeck BV, Amsterdam, The Netherlands; 2Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; 3Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; 4Creativ Research SAS, Paris, France; 5Global Evidence and Value Development, Sanofi-Aventis, Paris, FranceObjective: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer's disease in the Nethe... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Original Research |
Erscheinungsdatum: | 2011 |
Verlag/Hrsg.: |
Dove Press
|
Schlagwörter: | Neuropsychiatric Disease and Treatment |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26804994 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://www.dovepress.com/cost-effectiveness-analysis-of-memantine-for-moderate-to-severe-alzhei-peer-reviewed-fulltext-article-NDT |